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Long-term in vitro maintenance of clonal abundance and
leukaemia-initiating potential in acute lymphoblastic
leukaemia
D Pal1, HJ Blair1, A Elder1, K Dormon1, KJ Rennie2, DJL Coleman1, J Weiland1,3, KS Rankin1, A Filby4, O Heidenreich1 and J Vormoor1,5
Lack of suitable in vitro culture conditions for primary acute lymphoblastic leukaemia (ALL) cells severely impairs their experimental
accessibility and the testing of new drugs on cell material reflecting clonal heterogeneity in patients. We show that Nestin-positive
human mesenchymal stem cells (MSCs) support expansion of a range of biologically and clinically distinct patient-derived ALL
samples. Adherent ALL cells showed an increased accumulation in the S phase of the cell cycle and diminished apoptosis when
compared with cells in the suspension fraction. Moreover, surface expression of adhesion molecules CD34, CDH2 and CD10
increased several fold. Approximately 20% of the ALL cells were in G0 phase of the cell cycle, suggesting that MSCs may support
quiescent ALL cells. Cellular barcoding demonstrated long-term preservation of clonal abundance. Expansion of ALL cells for
43 months compromised neither feeder dependence nor cancer initiating ability as judged by their engraftment potential in
immunocompromised mice. Finally, we demonstrate the suitability of this co-culture approach for the investigation of drug
combinations with luciferase-expressing primograft ALL cells. Taken together, we have developed a preclinical platform with
patient-derived material that will facilitate the development of clinically effective combination therapies for ALL.
Leukemia advance online publication, 10 June 2016; doi:10.1038/leu.2016.79
INTRODUCTION
Robust preclinical models for childhood acute lymphoblastic
leukaemia (ALL) are essential for dissecting mechanisms that drive
malignant growth and survival and to test and develop novel
targeted therapies that may improve current therapies with
regard to efficacy and toxicity. Cell line models have been widely
used in functional in vitro studies and preclinical drug screens.1–6
Although cell lines do retain the original driver mutations, they
do not represent the molecular complexity of the disease at
presentation. More importantly, cell lines have adapted to
suspension culture and grow without niche support. The
combination of low complexity and reduced dependence on
cell-extrinsic signalling can affect the translation of cell line data to
the clinical situation, for example, in relation to clinically relevant
mechanisms of drug resistance; 7–9 thus affecting the ability of cell
line models to reflect the original disease.
Functional studies with primary blasts from children with
ALL, however, have been hampered by the difficulty in expanding
ALL cells in vitro. ALL blasts are highly dependent on their in vivo
environment and rapidly undergo apoptosis ex vivo.10–12 Short-
term in vitro assays have been developed for testing drug
sensitivity;13 however, their use has not been widely implemented
because of the rapid decline of ALL cells in these assays, even
without exposure to any anti-leukaemic compounds.
The vast majority of ALL will engraft at low cell numbers and
proliferate in highly immunodeficient mice.14–16 These studies
have demonstrated that the murine bone marrow and lymphoid
microenvironment is highly conserved between mice and men
and able to support malignant human lymphoid cells. Although
there is some evidence of clonal selection in the mice,17–20 clonal
complexity and niche dependency are preserved.18 Xenograft
mouse models have been used for a wide range of studies
including the phenotypic definition and homing of leukaemia
propagating cells and for preclinical drug testing.6,16,21–24 How-
ever, animal experiments are labour intensive, expensive and time
consuming, thus limiting their application.
The group of Campana11,25 has pioneered novel culture systems
providing stroma support for the leukaemia blasts using
immortalised mesenchymal stem cells (MSCs). These and similar
bone marrow stromal co-cultures have been successfully used to
model leukaemia–stroma adhesions and interactions.26–30 Stroma
cells provide crucial survival signals to the leukaemic cells
that affect drug resistance, thus mimicking the situation in
patients.10,31–34 However, despite the ability of allogeneic bone
marrow stromal cells to support proliferation of primary leukaemia
blasts, acquisition of additional mutations following long-term cell
expansion has been observed. This reduces the complexity and
feeder dependence of the cultivated blasts, sometimes leading to
the outgrowth of cell lines.27,28,35
We describe an optimised primary MSC culture system for the
long-term propagation of a cytogenetically and clinically distinct
panel of primary and primograft ALL blasts in vitro without
compromising sample clonal composition and self-renewal
capacity. We confirm early-passage primary MSCs to provide
1Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, UK; 2Musculoskeletal Research Group, Institute of Cellular
Medicine, Newcastle University, Newcastle Upon Tyne, UK; 3Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH
Aachen University, Aachen, Germany; 4Flow Cytometry Core Facility, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK and 5Great North Children’s
Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK. Correspondence: Professor O Heidenreich or Professor J Vormoor, Northern Institute
for Cancer Research, Newcastle University, Paul O'Gorman Building, Medical School, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK.
E-mail: olaf.heidenreich@newcastle.ac.uk or josef.vormoor@newcastle.ac.uk
Received 5 August 2015; revised 18 March 2016; accepted 30 March 2016; accepted article preview online 25 April 2016
Leukemia (2016), 1–10
© 2016 Macmillan Publishers Limited All rights reserved 0887-6924/16
www.nature.com/leu
superior support than their counterpart feeders in B-ALL expansion.
Combining MSC co-culture with lentiviral luciferase transduction of
ALL cells generates an experimentally accessible medium–high
throughput in vitro system that is suitable for preclinical
drug testing in patient-derived primary leukaemic cells.
MATERIALS AND METHODS
Drug combination screen
This assay was carried on white frame and clear flat-bottom 96-well plates
(Santa Cruz Biotechnology, Heidelberg, Germany) seeded with 10 000
MSCs per well. L707 cells were lentivirally transduced with pHR-cppt-SLIEW
for stable expression of enhanced green fluorescent protein and firefly
luciferase followed by sorting for green fluorescent protein positivity
on a FACS Aria III (BD Biosciences, Oxford, UK) and expansion on MSCs for
2 weeks.36 For drug treatment, green fluorescent protein-positive ALL cells
were seeded onto the 96-well plates at 5000 cells per well followed by
incubation with clinically relevant drug concentrations. Dose response was
analysed 5 days later by adding luciferin at 30 μg/ml (Promega,
Southampton, UK) and measuring bioluminescence using the FLUOstar
Omega microplate reader (BMG, Ortenberg, Germany). Combination
indices were calculated for drug combinations in constant ratio to each
other using software CalcuSyn Version 2.1.37
RESULTS
MSCs support short-term proliferation of a range of clinically
distinct patient-derived ALL cells
To compare the impact of stromal cell lines and primary human
MSCs on B-ALL propagation, we examined ALL cell proliferation
on either the murine stromal cell line M2-10B4, human
TERT-immortalised MSC or primary human MSCs obtained from
hip surgery.
Primary MSCs were characterised as NES+ CD73+ CDH2+
CD90++ TEK+ (expression of all these markers was homogenous
across all MSCs); absence of haematopoietic cells was confirmed
by lack of CD45 and CD19 surface expression (Supplementary
Figure S3). We examined the growth of the t(12;21)-positive
B-lineage ALL line REH on the feeder systems at very low cell
concentration and low fetal calf serum condition. Under these
conditions, REH cell numbers dropped ninefold within a week.
In contrast, co-incubation with either M2-10B4 or MSCs resulted in a
5-fold and 15-fold increase in cell number, respectively, suggesting
a superior growth-promoting role for human MSCs compared with
the murine stroma cell line (Supplementary Figure S4).
Next, we studied the ex vivo expansion of ALL primograft
material on these feeders. Replacement of RPMI-1640 by serum-
free expansion medium and 20% fetal calf serum resulted in
superior survival of primograft material (Supplementary Figure S5).
Nevertheless, a t(9;22)-positive ALL primograft from patient L4951
showed poor viability and a more than fivefold reduced cell
number in suspension culture that was only marginally improved
by co-incubation with M2-10B4 cells (Figure 1a). However,
co-culture on TERT-immortalised MSCs confirmed improved viability
and successful maintenance of cell numbers, whereas incubation
on an early-passage primary human MSC layer not only preserved
primograft viability, but also induced formation of cobblestone
pattern and 24-fold increased cell numbers indicating more than
4 cell doublings over 7 days (Figures 1a–c and Supplementary
Figure 1. MSCs support ALL propagation in vitro. (a) Proliferation of L4951 cells without feeder, with murine M2-10B4, with TERT-MSC and with
human MSC feeders. (b) Phase-contrast photographs of patient-derived B-ALL cells in suspension monocultures and in co-culture with MSCs.
(c) Formation of cobblestone colonies by ALL cells on MSCs. (d) Proliferation of a panel of B-ALLs over 7 days without and with MSC feeder.
For karyotype information see Supplementary Table S1. N⩾ 3 for all experiments shown; error bars, s.d.
ALL expansion on MSCs
D Pal et al
2
Leukemia (2016) 1 – 10 © 2016 Macmillan Publishers Limited
Figure S6). Furthermore, consistent with other existing reports,38
we confirm reduced Nestin expression in the TERT-MSC cells
(Supplementary Figure S6).
We extended these cultures to a panel of nine different B-ALL
primografts and two primary B-ALL samples (L880, L826) that had
not been previously passaged through a mouse (Supplementary
Table S1). Whereas all ALLs showed reduced cell numbers within
1 week of liquid culture, co-incubation with MSCs increased
cell numbers by 1.5–30-fold (Figure 1d).
Cell adherence instructs cell-cycle status and phenotype of the
leukaemic blasts
Cell cycle analysis showed that co-culture on MSCs caused a
twofold increase in ALL cells being in the S phase and a 20-fold
reduction in subG1 cell numbers indicating a substantial inhibition
of apoptosis (Figures 2a–c and Supplementary Figures S1 and S7).
Interestingly, closer inspection of the cell cycle distribution of
treatment relapse ALL cells on MSCs using combined Hoechst/
Pyronin Y staining revealed a subset of 435% ALL cells being in
G0, suggesting that MSCs may support dormant leukaemic
cells (Figure 2d). Furthermore, when comparing the matched
diagnostic and relapse sample of patient L707, we observed a
more than twofold higher fraction of G0 cells in the relapse
(Figure 2e).
A more detailed examination showed that this effect is limited
to ALL cells adhering to the MSC layer. Nonadherent ALL cells
showed subG1 and S-phase distributions similar to ALL cells
in standard suspension culture (Figure 2f), that is, a high rate of
apoptosis. Notably, MSC-conditioned medium was not sufficient
to promote growth of primograft ALL, indicating that direct
cell–cell contact is required for the propagation of patient ALL
cells (Figures 2g and h and Supplementary Figure S8).
Figure 2. Impact of MSC co-culture on viability and cell cycle distribution of B-ALL cells from patient L707. (a) Cell cycle analysis of L707
(E2A/HLF) B-ALL cells. Also see Supplementary Figure S7 for other samples. (b) Fluorescence-activated cell sorting (FACS) analysis of subG1
fractions of ALL cells. Also see Supplementary Figure S7 for other samples. (c) Apoptosis in L707 cells analysed by Annexin V/propidium iodide
staining. (d) Detection of G0 ALL cells by Hoechst 33342/Pyronin Y staining. Left panel=None; Right panel=MSC (e) Quantitation of L707
relapse and presentation cells in G0 phase. (f) Analysis of cell cycle distribution of L707 cells in suspension and adhered to MSC layer.
(g) Phase-contrast photographs of ALL cells in MSC-conditioned medium and in direct co-culture with MSCs. (h) FACS cell-cycle analysis of
subG1 ALL cells cultured with MSCs or in MSC-conditioned medium. N⩾ 3 for all experiments shown; error bars, s.d.
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Most importantly, adherence to MSC affects the expression of
genes likely to be involved in cell–cell communication. Surface
expression of CD34 (a cell surface glycoprotein involved in cell
adhesion), Cadherin 2 (CDH2; a transmembrane gene involved in
the formation of adherens junctions) and CD10 (a cell surface
enzyme with metalloendopeptidase activity) was between
two- and five-fold higher in adherent than nonadherent ALL cells
(Figure 3a and Supplementary Figure S2). Some nonadherent ALL
cells can adhere to MSCs upon transfer to a fresh monolayer and
start to proliferate (Figure 3c).
In addition, long-term ALL expansion over 4 weeks retained the
expression of CD10 and CD34 (Figure 3b), unlike in previously
published studies where altered immunophenotype in ALL cells
has been documented in vitro.35 Importantly, we observed a
drastic reduction in CD10 levels in suspension cultures as opposed
to the ALL cells on MSC that continually retained CD10 expression
over a 4-week period (Figure 3d). This is consistent with previous
reports documenting loss of CD10 in suspension cultures and its
expression to correlate with ALL progression in vivo.39,40
These combined findings indicate that direct cell–cell contact
with MSCs is required to maintain and propagate ALL in vitro and
that a fraction of the ALL cells in a suspension retain the ability
to reinitiate growth when brought back into contact with MSCs.
MSCs support long-term proliferation of five clinically distinct ALL
samples without altering clonal composition
To examine long-term expansion, we serially replated ALL
cells on new MSC layers. In these experiments, we studied the
proliferation of five primografts (L826; L4951; L707, L868; L754)
and two primary samples (L826; L880) representing a spectrum
of cytogenetically distinct ALLs (Supplementary Table S1). All
samples showed sustained proliferation for at least 20 days when
weekly replated on MSC layers (Figure 4a and Supplementary
Figure S9). Doubling times ranged from 1.5 to 4 days for
primograft ALL cells and 6 to 7 days for the primary ALL samples
(Figure 4b).
Selected primograft samples, including L707, could be main-
tained for more than 80 days in continuous culture, indicating a
potentially unrestricted growth potential under these conditions
(Figure 5a). ALL cells ceased proliferating when separated from the
MSC feeder layer and entered apoptosis as indicated by a
substantial increase in subG1 cells and Annexin V+ PI+ cells. In
contrast, cells continued proliferation when maintained on MSC
feeders (Figures 5b–d and Supplementary Figure S10). These data
show that it is possible to maintain primary and primograft ALL
cells in tissue culture for prolonged periods of time, without
generating cell lines that are able to proliferate independent of
feeder support. However, for some leukaemias, prolonged culture
on MSCs led to decelerated cell growth (L707) whereas other
samples (L754; L880; L826; 19578), although remaining viable,
completely ceased proliferation after 20 days and expressed
senescence-associated β-galactosidase (Figures 5e and f).
Cellular barcoding is a process by which cells are tagged by a
unique DNA sequence (the ‘barcode’) that upon stable integration
confers a heritable mark so as to trace clonal progenies.41
This clonal analysis technique is commonly used for the purposes
of evaluating clonal dynamics such as clonal complexity, clonal
dominance and founder effects.19,42,43 We used this cellular
barcoding approach as an in vitro tool for clonal tracing so as to
evaluate whether such prolonged ex vivo expansion would cause
any MSC-related bottleneck. L4951-BCR/ABL cells were lentivirally
transduced with a custom-made barcoded vector library.36,43
Five million cells containing 897 different barcoded clones were
seeded onto MSCs. Following 4 weeks of in vitro culture on MSCs,
100% of the barcodes in the baseline sample were retrieved,
indicating unaltered clonal complexity on the MSC cultures. In
addition, there was no selection of dominant clones (Figure 5g).
Additional experiments with L707-E2A/HLF and P929-MLL/AF4
further confirmed retention of a high degree of clonal complexity
in addition to unaltered clonal composition at varying barcode
complexities (Figure 5h and Supplementary Figure S11). Barcodes
that were lost completely following MSC co-culture were already
Figure 3. MSC co-culture preserves the ALL immunophenotype. Fluorescence-activated cell sorting (FACS) analysis of CD19, CD34, CD10 and
N-cadherin (CDH2) expression. Grey, isotype control; black, nonadherent; grey fill, adherent. (b) FACS analysis of CD10 and CD34 expression on
L707 ALL cells following 30-day co-culture on MSCs. (c) Cell-cycle analysis of suspension ALL cells compared with adherent cells. Here
adherent refers to previously suspension ALL cells that adhered when transferred on to a fresh MSC layer. (d) FACS analysis of CD10 surface
expression on L707 ALLs in suspension monocultures and in co-cultures on MSC. N⩾ 3 for all experiments shown; error bars, s.d.
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rare (o0.1%) in the baseline sample, suggesting this phenom-
enon to be a stochastic effect. This further suggests that long-term
expansion of ALL on MSCs does not significantly limit clonal
complexity or lead to clonal dominance, making this model an
appropriate tool for investigating clonal dynamics in vitro.
Prolonged expansion on MSCs preserves engraftment potential
of ALL cells
Prolonged expansion of primary leukaemic cells frequently impairs
their self-renewal capacity and, consequently, their ability to
induce leukaemia in immunodeficient mice.34 Therefore, we
examined whether extended MSC co-culture affects the engraft-
ment potential of primograft cells. We used two primografts (L707
and L826) that had been transduced to stably express
luciferase.6,36 Consequently, engraftment of these primografts
can be monitored in vivo using bioluminescent imaging. For the
t(17;19)-positive L707 sample, co-culture on MSC feeder for
8 weeks did not diminish the engraftment potential when
compared with uncultured primograft cells (Figures 6a and c). In
both settings, mice showed the characteristic leukaemic
spread including infiltration of spleen, spine, sternum and calvaria
within 4 weeks after transplantation (Figures 6a and c and
Supplementary Figure S12). The t(4;11)-positive ALL primograft
L826 was cultured on MSC for 4 weeks prior transplantation. These
cells showed an even accelerated leukaemic engraftment and
spread compared with directly thawed from frozen starting
material, possibly because of a higher viability of the ALL cells
following MSC co-culture as compared with the freshly thawed
sample (Figures 6b and d). This retention of leukaemia-initiating
potential demonstrates that prolonged culture on MSCs maintains
the self-renewal capacity of patient-derived ALL samples.
MSC co-culture allow bioluminescence-based drug combination
screens with patient-derived ALL cells
Finally we examined the suitability of the ALL/MSC− co-culture
system for the evaluation of therapeutic compounds. In an initial
experiment, we asked whether this system faithfully reflects
clinically observed drug responses. We treated a matched
presentation/relapse pair of the fatal E2A/HLF-positive transloca-
tion samples (L707 and L707R, respectively) with dexamethasone
(Figure 7a). At diagnosis, the corresponding patient from whom
these samples were derived from responded to dexamethasone,
but gained resistance upon relapse through loss of the steroid
receptor. Both samples proliferated on MSC layers (Figure 1d).
Treatment with dexamethasone for 1 week reduced cell numbers
of the presentation sample more than twofold, whereas the
relapse sample continued to proliferate (Figure 7b). This was
paralleled by an 80-fold increase in apoptosis in the presentation
sample, whereas the relapse showed only a negligible induction of
apoptosis (Figure 7c). Therefore, for this patient and for treatment
with dexamethasone, the in vitro co-culture system recapitulates
clinically observed treatment responses.
To improve the co-culture assay and create an up-scalable
tool for high-throughput screening, we started to use
bioluminescence-labelled primary ALL cells36 that allows live
monitoring of cell numbers in 96-well plates in response to single
and combinations of candidate anti-leukaemic drugs (Figure 7d).
In the first instance, we assessed proven drug combination
response on our platform to corroborate its credibility in
predicting documented drug efficacies. MSC feeders were
established in 96-well plates and seeded with dexamethasone-
sensitive L707-E2A/HLF cells stably expressing luciferase. The
co-cultures were then exposed to increasing concentrations of
dexamethasone alone (Figure 8a) and in combination with the
BCL2 inhibitor ABT-199 (Figure 8f). Cell numbers were monitored
through bioluminescence. Even at the lowest concentration,
dexamethasone reduced cell counts by fivefold. Furthermore,
consistent with existing literature,44 we confirm synergism of
dexamethasone/ABT-199 (combination index (CI) = 0.32) in our
MSC bioluminescence-based drug assay. We repeated the drug-
combination experiment with another primary sample (L826-MLL/
AF4) and in accordance with reported literature45 confirmed a
combination of DOT1L inhibitor EPZ5676 and ABT-199 (CI = 0.39)
to be synergistic in MLL rearranged leukaemia (Figures 8c, d and g).
We and others have previously shown BCL2 to be active in
t(9;22) ALL.6,46 In this context we identify drug combination
imatinib/ABT-199 to show synergism in BCR/ABL leukaemia
(CI = 0.88) (Figures 8b, e and h). These data confirm credibility of
the bioluminescence MSC-based model as a new experimental
platform for medium–high throughput in vitro testing of drug
combinations and further suggest that the combination of
ABT-199 with Imatinib may warrant further investigation for the
treatment of very high risk ALL/t(9;22).
DISCUSSION
In this paper we show that primary and patient-derived ALL cells
can be successfully expanded ex vivo often over prolonged
periods of time, without loss of leukaemic self-renewal potential
and while maintaining the multitude of founder clones in these
cultures.
MSCs play an important role in the normal haematopoietic and
leukaemic bone marrow niche.47–49 In particular, in vivo studies
have shown that following cytotoxic treatment MSC cooperate
with B-ALL cells to create a supportive microenvironment that
Figure 4. Growth kinetics of B-ALL cells on MSCs. (a) Growth curve
of primary L826 ALL cells on MSC over a 4-week period. (b) Plot
representing population doubling times for long-term culture of five
different B-ALL samples on MSCs. tD=doubling time. N⩾ 3 for all
experiments shown; error bars, s.d.
ALL expansion on MSCs
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confers chemoprotection.48 Consistent with these in vivo and
previous in vitro studies,11,12,32,50 we confirm that freshly sourced
low-passage Nestin-positive MSCs are able to provide superior
support for long-term in vitro expansion of primary and patient-
derived lymphoid blasts compared with murine M210B4 or human
TERT-immortalised MSCs. Through fate mapping we show that
hundreds of founder clones establish the leukaemia in these
cultures, continue to contribute to the in vitro expanding
leukaemia over time and maintain the ability to re-establish the
disease in immunodeficient mice.
Direct MSC contact is required to support proliferation and
viability of B-ALL and cannot be substituted by MSC conditioned
medium. A possible mechanism behind this contact-mediated
survival may be attributed to the formation of tunnelling
nanotubules between the MSCs and B-ALL cells.51 Adherence to
MSCs is an interactive process leading to the upregulation of key
molecules on the surface of the leukaemic blasts that are
presumed to play a role in cell–cell contacts. This was shown for
the cell adhesion molecule CD34 and, more importantly, for
cadherin 2 that is involved in establishing tight adhesion junctions
between cells. Another molecule upregulated upon adhesion to
MSCs but lost in suspension culture was CD10. CD10 is a cell
surface molecule with metalloprotease activity that is able
to inactivate a range of peptide hormones and as such expected
to regulate signals from the microenvironment. Similar to our
observation, CD10 has been shown to be induced and to correlate
with progression of ALL in vivo while being lost in vitro during
suspension culture;39,40 it has also been shown to correlate with
dissemination and progression of melanoma and other types
of cancer.52
Figure 5. Long-term propagation of ALL cells on MSCs. (a) Biphasic growth curve of L707 in long-term co-culture with MSCs. (b) Impact of
MSC removal on ALL proliferation. L707 cells were either continuously co-cultured on MSCs or after 21 days separated from MSCs (broken
line). Cell counts show that B-ALL cells replated on MSCs continued to proliferate, whereas the suspension cells died out within a week.
(c) Phase-contrast photograph showing B-ALL cells on MSC before feeder removal, B-ALL cells 7 days following feeder removal and post-MSC-
separated B-ALL cells when replated onto fresh MSCs. (d) Percentage of L707 ALL cells in subG1 on feeders at days 21 and 7 days after removal
from the MSC feeder at day 28. (e) Cell-cycle analysis of L707 and L754 cells after 5 weeks of co-culture with MSCs. G0 cells were quantified by
Hoechst 33342/Pyronin Y G0 staining. (f) Senescence-associated β-galactosidase staining of L754 colonies following week 5 of co-culture on
MSCs. N⩾ 3 for all experiments shown; error bars, s.d. (g, h) Clonal composition of barcoded L4951 and L707 cells prior (baseline) and after
long-term (4–6 weeks) expansion on MSCs. Each colour represents a distinct clone (L4951= 17, L707= 23 clones both pre- and post-MSCs) and
hatched area represents remaining rarer clones (L495141050, L7074550 clones both pre- and post-MSCs).
ALL expansion on MSCs
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Figure 6. In vivo engraftment of patient-derived B-ALL cells following long-term expansion on MSC. (a, b) In vivo imaging of luciferase-tagged
L707 (a) (N= 6 experiments) and L826 (b) (N= 4 experiments) B-ALL cells after 8 and 4 weeks of MSC co-culture, respectively. Bottom panels
show control engraftment of the corresponding frozen primograft. Note the similarity of L707 engraftment in terms of organ spread especially
as central nervous system (CNS, spinal) involvement is classically seen with the L707 control samples. (c, d) Bioluminescence reading of total
flux shows comparable patterns in the rate of engraftment between control and B-ALL–MSCs. Error bars, s.d.
Figure 7. Patient-derived ALL drug screen. (a–c) Phase-contrast photographs (a), cell counts (b) and cell-cycle analysis (c) of L707 presentation
and relapse (L707 and L707R) cells with and without Dexamethasone. N= 3 experiments; error bars, s.d. (d) A scheme of testing low-molecular-
weight compounds (LMWCs) in a bioluminescent ALL–MSC co-culture system. Primograft cells were lentivirally transduced to stably express
firefly luciferase.
ALL expansion on MSCs
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Interestingly, our cell cycle analyses show that a high number of
ALL blasts go into cell cycle arrest (G0) upon direct contact with
MSCs. This could be seen as a limitation of this assay as not all ALL
samples will continue to proliferate and expand long term;
however, it provides a tool to study the mechanisms that regulate
quiescence/dormancy of leukemic cells. In summary, the ALL/MSC
co-culture system provides an experimentally accessible model to
study and dissect key components of the leukaemic niche,
including how the niche facilitates chemoprotection.
Drug response validation experiments show that in vitro
response in the ALL/MSC co-culture assay correlates with clinical
and in vivo responses, as shown here for steroid and targeted
Figure 8. Bioluminescent drug combination screen using patient-derived ALL. (a–e) Dose-related response as depicted by decreasing
bioluminescence using single-drug targeted pharmacotherapy. The 100% relative luminescence refers to untreated control. (a)
Dexamethasone on L707-E2A/HLF, (b) BCL2 inhibitor ABT-199 on L4951-BCR/ABL and (c) L826-MLL/AF4, (d) DOT1L inhibitor EPZ5676 on
L826-MLL/AF4 and (e) imatinib on L4951-BCR/ABL. (f–h) Synergistic drug combinations. (f) Dexamethasone/ABT-199 (combination index
(CI)= 0.32 at half-maximal effective dose (ED50)) on L707-E2A/HLF, (g) EPZ5676/ABT-199 (CI= 0.39 at ED50) on L826-MLL/AF4 and (h) imatinib/
ABT-199 (CI= 0.88) on L4951-BCR/ABL. N= 3 for all experiments shown; error bars, s.d.
ALL expansion on MSCs
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drug-combination sensitivities. Testing novel agents on primary
and primografted cells on MSC co-cultures will increase the
predictive value for clinical responses as compared with
historic suspension culture assays. To further improve the assay
system compared with previously published MSC co-culture
models10–12,32,50 and to create an up-scalable tool for high-
throughput screening, we introduced bioluminescence-labelled
ALL cells allowing live monitoring of cell numbers in 96-well plates
in response to combinations of candidate anti-leukaemic drugs.
Although not all ALL samples grow long term on MSCs, using
bioluminescent-labelled patient-derived ALL cells after expansion
through immunodeficient mice (primografts), this assay will
significantly simplify preclinical drug testing by using a clinically
relevant cell source and by improved modelling of the in vivo
microenvironment while significantly reducing expensive in vivo
experiments that are currently regarded as gold standard assays
for preclinical drug development. Most importantly, as we show
that the MSCs preserve the initial multitude of leukaemic founder
clones, this assay will allow complex functional RNAi/CRISPR (RNA
interference/clustered regularly interspaced short palindromic
repeats) screens to study synthetic lethality, thereby facilitating
design of novel and clinically effective combination therapies
for ALL.
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